RESUMO
A 1,2,4-triazole motif was employed as a bioisostere for the ester commonly used in muscarinic antagonists, and subsequent integrative conjugation to a ß2 agonist quinolinone furnished a new class of bifunctional MABAs for the treatment of COPD. Medicinal chemistry optimization using the principles of 'inhalation by design' furnished a clinical candidate with desirable pharmacological, pharmacokinetic and biopharmaceutical properties.
Assuntos
Agonistas de Receptores Adrenérgicos beta 2/síntese química , Broncodilatadores/síntese química , Antagonistas Muscarínicos/síntese química , Doença Pulmonar Obstrutiva Crônica/tratamento farmacológico , Triazóis/síntese química , Agonistas de Receptores Adrenérgicos beta 2/farmacocinética , Agonistas de Receptores Adrenérgicos beta 2/farmacologia , Animais , Disponibilidade Biológica , Broncoconstrição/efeitos dos fármacos , Broncodilatadores/farmacocinética , Broncodilatadores/farmacologia , Células CHO , Cricetulus , Cães , Humanos , Ipratrópio/farmacologia , Antagonistas Muscarínicos/farmacocinética , Antagonistas Muscarínicos/farmacologia , Ratos , Receptor Muscarínico M3/antagonistas & inibidores , Xinafoato de Salmeterol/farmacologia , Brometo de Tiotrópio/farmacologia , Triazóis/farmacocinética , Triazóis/farmacologiaRESUMO
The transient receptor potential (TRP) family of ion channels comprises nonselective cation channels that respond to a wide range of chemical and thermal stimuli. TRPM8, a member of the melastatin subfamily, is activated by cold temperatures (<28 °C), and antagonists of this channel have the potential to treat cold induced allodynia and hyperalgesia. However, TRPM8 has also been implicated in mammalian thermoregulation and antagonists have the potential to induce hypothermia in patients. We report herein the identification and optimization of a series of TRPM8 antagonists that ultimately led to the discovery of PF-05105679. The clinical finding with this compound will be discussed, including both efficacy and its ability to affect thermoregulation processes in humans.
RESUMO
This paper describes the successful design and development of dual pharmacology ß-2 agonists-M3 antagonists, for the treatment of chronic obstructive pulmonary disorder using the principles of 'inhalation by design'. A key feature of this work is the combination of balanced potency and pharmacodynamic duration with desirable pharmacokinetic and material properties, whilst keeping synthetic complexity to a minimum.
